Aptorum Group Limited
APM
Price:
$2.81
Market Cap:
$14.56M
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), ...[Read more]
Industry
Biotechnology
IPO Date
2018-12-18
Stock Exchange
NASDAQ
Ticker
APM
The ROE as of September 2024 (TTM) for Aptorum Group Limited (APM) is -12.10%
According to Aptorum Group Limited’s latest financial reports and current stock price. The company's current ROE is -12.10%. This represents a change of -25.28% compared to the average of -16.19% of the last 4 quarters.
Aptorum Group Limited (APM) Historical ROE (quarterly & annually)
How has APM ROE performed in the past?
The mean historical ROE of Aptorum Group Limited over the last ten years is -45.16%. The current -12.10% ROE has changed -73.21% with respect to the historical average. Over the past ten years (40 quarters), APM's ROE was at its highest in in the December 2020 quarter at 31.72%. The ROE was at its lowest in in the December 2019 quarter at -58.66%.
Average
-45.16%
Median
-33.82%
Minimum
-127.46%
Maximum
16.89%
Aptorum Group Limited (APM) ROE by Quarter and Year
Discovering the peaks and valleys of Aptorum Group Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 431.74%
Maximum Annual ROE = 16.89%
Minimum Annual Increase = -734.13%
Minimum Annual ROE = -127.46%
| Year | ROE | Change |
|---|---|---|
| 2023 | -11.37% | -66.39% |
| 2022 | -33.82% | -68.42% |
| 2021 | -107.12% | -734.13% |
| 2020 | 16.89% | -113.25% |
| 2019 | -127.46% | 184.58% |
| 2018 | -44.79% | 431.74% |
Aptorum Group Limited (APM) Average ROE
How has APM ROE performed in the past?
The current ROE of Aptorum Group Limited (APM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-50.77%
5-year avg
-52.58%
10-year avg
-45.16%
Aptorum Group Limited (APM) ROE vs. Peers
How is APM’s ROE compared to its peers?
Aptorum Group Limited’s ROE is less than ERYTECH Pharma S.A. (6.80%), greater than Surrozen, Inc. (-178.66%), less than Unicycive Therapeutics, Inc. (294.74%), less than Armata Pharmaceuticals, Inc. (182.35%), greater than Applied Molecular Transport Inc. (-218.56%), greater than Fresh Tracks Therapeutics, Inc. (-58.16%), greater than AIM ImmunoTech Inc. (-256.33%), less than BioCardia, Inc. (526.79%), greater than Innate Pharma S.A. (-20.69%), greater than Addex Therapeutics Ltd (-456.73%), greater than Celyad Oncology SA (-170.72%), greater than Dyadic International, Inc. (-145.95%), greater than Altamira Therapeutics Ltd. (-233.96%), greater than Dermata Therapeutics, Inc. (-197.44%), less than ContraFect Corporation (403.13%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Aditxt, Inc. (-607.01%), greater than NeuroBo Pharmaceuticals, Inc. (-154.04%), greater than Revelation Biosciences, Inc. (-243.91%),
| Company | ROE | Market cap |
|---|---|---|
| 6.80% | $47.38M | |
| -178.66% | $27.92M | |
| 294.74% | $35.51M | |
| 182.35% | $79.24M | |
| -218.56% | $11.01M | |
| -58.16% | $4.45M | |
| -256.33% | $17.51M | |
| 526.79% | $9.91M | |
| -20.69% | $175.66M | |
| -456.73% | $15.93M | |
| -170.72% | $14.24M | |
| -145.95% | $37.14M | |
| -233.96% | $1.68M | |
| -197.44% | $2.79M | |
| 403.13% | $1.72M | |
| 2.18% | $223.46K | |
| -607.01% | $2.53M | |
| -154.04% | $30.52M | |
| -243.91% | $1.50M |
Build a custom stock screener for Aptorum Group Limited (APM) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aptorum Group Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Aptorum Group Limited (APM) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Aptorum Group Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Aptorum Group Limited's ROE?
How is the ROE calculated for Aptorum Group Limited (APM)?
What is the highest ROE for Aptorum Group Limited (APM)?
What is the 3-year average ROE for Aptorum Group Limited (APM)?
What is the 5-year average ROE for Aptorum Group Limited (APM)?
How does the current ROE for Aptorum Group Limited (APM) compare to its historical average?